Science Exchange, the leading marketplace for outsourced R&D, announced today a collaboration with Renovo Neural, a Contract Research Organization (CRO) specializing in degenerative neurological conditions.
Renovo has a history in model development for multiple sclerosis (MS) and recently expanded its efforts to offer other non-clinical research services such as immunohistochemistry and 3-D electron microscopy for a wide range of neurological disorders, including Parkinson’s Disease, Alzheimer’s Disease, and Charcot-Marie-Tooth Syndrome.
Renovo is best known for having developed an augmented cuprizone model of MS. This model – developed by the pioneering work of Bruce Trapp and Wendy Macklin – has been documented to provide superior reliability in evaluating the remyelination potential of novel therapeutic candidate compounds. Renovo has an experienced team and proven capabilities to support research and development in neurology.
“While Renovo is already well-known in the field, collaborating with Science Exchange will help expand our reach to researchers who can benefit from the technical expertise our team can provide,” stated Vivek Shenoy, CEO of Renovo. “We will be in a better position to support R&D teams actively involved in the discovery of new therapies to treat or even reverse the debilitating effects of MS and other neurodegenerative diseases.”
“We are very excited to collaborate with Renovo Neural to make its novel neurological research services readily available to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Science Exchange is committed to adding the most innovative and qualified service providers to our platform, so scientists have secure, rapid access to the services they need to aid their discoveries. Renovo Neural has impressed us with their progress in the field of neurodegenerative diseases.”
About Science Exchange
Science Exchange is the world's leading marketplace for outsourced R&D, providing large R&D organizations with the fastest path from discovery through development and commercialization. Science Exchange includes an efficient source-to-secure platform for ordering 6,000+ services from a network of more than 2,500 qualified outsourced research providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases access to innovation and improves productivity, freeing scientists from administrative tasks and delays associated with sourcing, establishing and managing service provider contracts.
Additionally, the Science Exchange enterprise program enables large R&D organizations to consolidate research outsourcing spend into a single strategic relationship, driving efficiency, improving transparency and oversight, and delivering cost savings. Since being founded in 2011, Science Exchange has raised more than $58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit www.ScienceExchange.com.
About Renovo Neural
Renovo Neural, Inc. is a private CRO operating in Cleveland, Ohio, for the past 10 years. The company was co-founded by Dr. Wendy Macklin and Dr. Bruce Trapp, Chief Scientific Officer of Renovo and the current chair of the Neuroscience Department at the Lerner Research Institute at the Cleveland Clinic. Drs. Macklin and Trapp are both recognized as world-renowned experts in Multiple Sclerosis research. The company offers pre-clinical / non-clinical translational research services with a focus on the evaluation of neuro-therapeutics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180928005063/en/
Contacts
Science Exchange
Gursatya "Guru" Singh
Director of Scientific Content
or
Renovo Neural, Inc.
Chris Ryan, +1 216-445-4202
Executive Director, Business Development
The information on this page is provided by Business Wire. All rights reserved. Reproduction or redistribution of this content without prior written consent from Business Wire is strictly prohibited. L.A. Biz is not responsible for this content.
https://www.bizjournals.com/losangeles/businesswire/press_releases/California/2018/09/28/20180928005063
No comments:
Post a Comment